IL6 and neoplasm: The observations for both agents were correlated, and an evident increase in MMD (the macrophage-representing marker) expression was found in the group treated twice with CD19 CAR-T cells (Figure 4a), with a significant upregulation of IL-6 at the tumor site in this group (Figure 4b).